Federal judges have halted the Department of Health and Human Services’ 340B Rebate Model Pilot Program, prompting the agency to consider revisiting the proposal. The pilot, originally set to begin Jan. 1, would have allowed select drug manufacturers to shift from traditional upfront 340B discounts to post‑sale rebates — a major structural change to a decades‑old program.

On Jan. 7, an appeals court upheld a lower court’s decision to block the pilot, agreeing that the model could move forward only after further review. Days later, a Jan. 12 letter from a Justice Department attorney indicated that HHS and the plaintiffs — including major hospital associations — are now “in discussions” about returning the proposal to the agency for reconsideration. The letter also noted that both parties expect to dismiss the appeal soon, signaling a pause in litigation while HHS reevaluates its approach.

The 340B program, established in 1992, requires drugmakers to provide upfront discounts on outpatient medications to eligible safety‑net providers such as disproportionate share hospitals, children’s hospitals, freestanding cancer centers, and rural referral centers. These entities accounted for $81.4 billion in 340B purchases in 2024.

Hospital groups have strongly opposed the rebate model since manufacturers first floated the idea in late 2024, warning that shifting to rebates would impose millions in new annual costs and create significant administrative burdens. Their lawsuit, filed in December, argues that the pilot violates the Administrative Procedure Act — an argument that both district and appellate courts have so far supported.

A Pause That Could Reshape the Future of 340B

The court‑ordered halt and HHS’ willingness to reconsider the rebate model mark a pivotal moment for the 340B program. As safety‑net hospitals continue to rely on upfront discounts to sustain care for vulnerable populations, any redesign of the program carries major financial and operational implications. The coming months will determine whether HHS revises the proposal, abandons it, or introduces a new framework altogether — and the outcome will shape how providers, manufacturers, and policymakers navigate 340B for years to come.